Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78520 | 0.81 | DGAT1 (0.46) | DGAT1CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL31458678 | 0.79 | DGAT1 (0.40) | DGAT1CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL5408152 | 0.78 | DGAT1 (0.36) | DGAT1CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL27463948 | 0.78 | DGAT1 (0.36) | DGAT1CHRM2CHRM1CHRM3NR1H2 | |
| SCHEMBL29399642 | 0.78 | — | — | |
| SCHEMBL19041123 | 0.76 | PPARA (0.36) | ALDH1A1 | |
| SCHEMBL11621321 | 0.75 | DGAT1 (0.42) | DGAT1CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL79871 | 0.75 | — | — | |
| Hydrazine SCHEMBL10794464 | 0.75 | DGAT1 (0.42) | DGAT1CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL15108015 | 0.75 | DGAT1 (0.42) | DGAT1CHRM2CHRM1CHRM3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103059046-B | Preparation method of faropenem | SUZHOU ERYE PHARMACEUTICAL CO | 2015-01-07 | — | — | CN | claimed |
| CN-103059046-A | Preparation method of faropenem | SUZHOU ERYE PHARMACEUTICAL CO | 2013-04-24 | — | — | CN | claimed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250367166-A1 | NEXT GENERATION DIPROVOCIMS THAT ACTIVATE THE INNATE AND ADAPTIVE IMMUNE RESPONSE | SCRIPPS RESEARCH INST (US) | 2025-12-04 | — | — | US | disclosed |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4440702-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4445900-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-0378429-A2 | Polymerisable compound and polymer therefrom | NIPPON PAINT CO., LTD. (JP) | 1990-07-18 | — | — | EP | disclosed |
| US-4940718-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0310214-A2 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1989-04-05 | — | — | EP | disclosed |
| US-4697033-A | INSECTICIDES | SANDOZ LTD. (CH) | 1987-09-29 | — | — | US | disclosed |
| EP-0095860-B1 | POLYMERISATION OF VINYL CHLORIDE MONOMER | ICI AUSTRALIA LIMITED (AU) | 1986-10-01 | — | — | EP | disclosed |
| US-4455412-A | LOW TEMPERATURE, VINYL CHLORIDE | ICI AUSTRALIA LIMITED (AU) | 1984-06-19 | — | — | US | disclosed |
| EP-0095860-A2 | Polymerisation of vinyl chloride monomer | ICI AUSTRALIA LIMITED (AU) | 1983-12-07 | — | — | EP | disclosed |
| US-4113880-A | ANTIALLERGENS | THE UPJOHN COMPANY (US) | 1978-09-12 | — | — | US | disclosed |
| US-3941821-A | ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETICS | WILLIAM H. RORER, INC. (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | DGAT1 1104/4885CHRM2 4705/4885CHRM1 4726/4885 |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | CD4, HAVCR2, MAVS | DGAT1 1104/4885CHRM2 4705/4885CHRM1 4726/4885 |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | DGAT1 1401/4885CHRM2 4598/4885CHRM1 4618/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | DGAT1 988/4885CHRM2 4790/4885CHRM1 4747/4885 |
| US-20250367166-A1 | NEXT GENERATION DIPROVOCIMS THAT ACTIVATE THE INNATE AND ADAPTIVE IMMUNE RESPONSE | TLR1, TLR4, TLR3 | DGAT1 2735/4885CHRM2 182/4885CHRM1 75/4885 |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CCR10, CCR1, CCR3 | DGAT1 1321/4885CHRM2 2831/4885CHRM1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.